Palatin Technologies Inc (NYSE MKT LLC:PTN)

0.9765
Delayed Data
As of 3:59pm ET
 +0.0165 / +1.72%
Today’s Change
0.59
Today|||52-Week Range
1.38
+33.77%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$40.5M

Company Description

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. It programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The company's primary product in development is bremelanotide for the treatment of female sexual dysfunction. It is also developing an inhalation formulation of peptide mimetic natriuretic peptide receptor A-agonist, for treatment of cardiovascular and pulmonary indications. Palatin Technologies was founded by Carl Spana and John K. A. Prendergast on November 21,1986 and is headquartered in Cranbury, NJ.

Contact Information

Palatin Technologies, Inc.
Cedar Brook Corporate Center
Cranbury New Jersey 08512
P:(609) 495-2200
Investor Relations:

Employees

Shareholders

Mutual fund holders3.90%
Other institutional23.93%
Individual stakeholders16.29%

Top Executives

Carl SpanaPresident, Chief Executive Officer & Director
Stephen T. WillsCFO, COO, Secretary, Treasurer & Executive VP
Jeff D. EdelsonChief Medical Officer
Stephen A. SlusherChief Legal Officer

To view my watchlist

Not a member yet?

Sign up now for a free account